Premium
Prevalence, Consequences, and Solutions
Author(s) -
Maki Dennis G.,
Safdar Nasia,
Ebert Steven C.
Publication year - 2007
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.27.10part2.121s
Subject(s) - antibiotic resistance , antibiotics , adversary , intensive care medicine , stewardship (theology) , antimicrobial stewardship , resistance (ecology) , infectious disease (medical specialty) , medicine , antimicrobial , antibiotic stewardship , disease , political science , biology , microbiology and biotechnology , computer security , computer science , law , pathology , ecology , politics
Since the early development of antibiotics, antimicrobial resistance has continued to emerge as a formidable adversary in the fight against infectious disease. Once an issue confined to hospitals, antibiotic resistance has now invaded communities, targeting not only the immunocompromised patient, but also those who are immunocompetent. To stem this crisis, researchers have developed more powerful and more costly antibiotics, which have only complicated the resistance problem. Education of the patient and the prescriber, as well as antimicrobial stewardship programs, are necessary to avert a global antibiotic resistance catastrophe.